-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Antiplatelet drugs and anticoagulants have been shown to reduce ischemic events in various clinical settings, including specific populations of patients with ischemic stroke or transient ischemic attack (TIA)
Primary efficacy outcomes (Primary efficacy outcomes) include safety factors, such as bleeding events.
Primary efficacy outcomes (Primary efficacy outcomes) include safety factors, such as bleeding events.
With ticagrelor and aspirin prevention of stroke and death in acute stroke or transient ischemic attack trial (Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and Aspirin for Prevention of Stroke and Death; THALES) indicates that this question
prevention
Its main efficacy outcome, namely stroke or death, including bleeding events, is also included in the main safety outcome
In addition, the first published results of THALES focused on relative risk, while absolute risk provided a more useful comparison of risks and benefits
In THALES, patients were randomly assigned to a 30-day ticagrelor plus aspirin regimen or a matching placebo plus aspirin regimen within 24 hours of the onset of symptoms
Stroke
Major ischemic events occurred in 11016 patients (5523 ticagrelor-aspirin and 5493 aspirin), 294 patients (5.
Major bleeding occurred in 22 patients (0.
The net clinical impact is in favor of ticagrelor-aspirin (absolute risk reduction 0.
The significance of this study lies in the discovery: in patients with mild to moderate ischemic stroke or high-risk TIA, the ischemic benefit of 30-day treatment with ticagrelor-aspirin outweighs the risk of bleeding
Original source:
Leave a message here
